Consensus-driven target product profiles for curative sickle cell disease gene therapies by Daima Bukini, Julie Makani, Joseph McCune, Dennis Lee, Cathy Bansbach, Serena De Vita, Dominic Kemps, Elianna Amin, Jonathan Spector, John Tisdale

Get full text

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. by Emily A Kendall, Sourya Shrestha, Ted Cohen, Eric Nuermberger, Kelly E Dooley, Lice Gonzalez-Angulo, Gavin J Churchyard, Payam Nahid, Michael L Rich, Cathy Bansbach, Thomas Forissier, Christian Lienhardt, David W Dowdy

Get full text

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens by Nicholas D. Walter, Sarah E. M. Born, Gregory T. Robertson, Matthew Reichlen, Christian Dide-Agossou, Victoria A. Ektnitphong, Karen Rossmassler, Michelle E. Ramey, Allison A. Bauman, Victor Ozols, Shelby C. Bearrows, Gary Schoolnik, Gregory Dolganov, Benjamin Garcia, Emmanuel Musisi, William Worodria, Laurence Huang, J. Lucian Davis, Nhung V. Nguyen, Hung V. Nguyen, Anh T. V. Nguyen, Ha Phan, Carol Wilusz, Brendan K. Podell, N’ Dira Sanoussi, Bouke C. de Jong, Corinne S. Merle, Dissou Affolabi, Helen McIlleron, Maria Garcia-Cremades, Ekaterina Maidji, Franceen Eshun-Wilson, Brandon Aguilar-Rodriguez, Dhuvarakesh Karthikeyan, Khisimuzi Mdluli, Cathy Bansbach, Anne J. Lenaerts, Radojka M. Savic, Payam Nahid, Joshua J. Vásquez, Martin I. Voskuil

Get full text